Targets › GBA
8 programs from 8 companies in 15 trials: 6 Phase 1, 5 Phase 3, 4 Phase 2; Neurology, Metabolic and endocrine, Hematology; next expected readout Feb 2027.
Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose. Plays a central role in the degradation of complex lipids and the turnover of cellular membranes. (UniProt, P04062)
Open in Phaseline: the race on GBA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Azafaros | Nizubaglustat (AZ-3102) Glucosidase inhibitor | GBA, UGCG | Phase 3 | Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 Gangliosidosis | Jun 2027 |
| Spur Therapeutics | FLT201 AAV-mediated gene therapy delivering functional GBA gene | GBA | Phase 3 | Gaucher Disease Type 1; Gaucher Disease, Type 1 | Jul 2028 |
| University College, London | Ambroxol Hydrochloride Glucocerebrosidase activator / lysosomal function enhancer | GBA | Phase 3 | Parkinson Disease | Feb 2029 |
| Chinese PLA General Hospital | Eliglustat Glucosylceramide synthase (GSL synthetase) inhibitor | GBA | Phase 2 | Colorectal Cancer; Lymphoma | Mar 2027 |
| Helse Fonna | Ambroxol Glucocerebrosidase (GCase) enhancing chaperone | GBA | Phase 2 | Dementia With Lewy Bodies | Sep 2027 |
| Bial R&D Investments | BIA 28-6156 Glucocerebrosidase activator | GBA | Phase 2 | Parkinson's Disease | – |
| Prevail Therapeutics | LY3884961 Recombinant adeno-associated virus (AAV) vector delivering GBA gene | GBA | Phase 1 | Gaucher Disease, Type 2; Gaucher Disease; Parkinson Disease | Feb 2027 |
| Lingyi Biotech | LY-M001 Injection rAAV8 vector gene therapy expressing glucocerebrosidase (GCase) | GBA | Phase 1 | Gaucher Disease Type 1 | Jul 2027 |
Parkinson Disease (2) Gaucher Disease Type 1 (2) Niemann-Pick Type C Disease (2) Colorectal Cancer (1) Lymphoma (1) Gaucher Disease, Type 1 (1) Gaucher Disease, Type 2 (1) Gaucher Disease (1) Gangliosidoses, GM2 (1) GM2 Gangliosidosis (1) Dementia With Lewy Bodies (1) Parkinson's Disease (1)
small molecule (5), other (3)
University College, London (1) Lingyi Biotech (1) Chinese PLA General Hospital (1) Spur Therapeutics (1) Prevail Therapeutics (1) Azafaros (1) Helse Fonna (1) Bial R&D Investments (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.